miR‑96 functions as a tumor suppressor gene by targeting NUAK1 in pancreatic cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• MicroRNA-96 (miR-96) is frequently downregulated in pancreatic cancer.
• The precise mechanisms by which miR-96 inhibits pancreatic cancer cell proliferation, migration, and invasion remain incompletely understood.
• Novel (nua) kinase family 1 (NUAK1) is implicated as an oncogene across multiple cancer types, including pancreatic cancer.

Purpose of the Study:

• To investigate the role of NUAK1 in pancreatic cancer progression.
• To determine if miR-96 directly targets NUAK1.
• To elucidate the functional consequences of the miR-96/NUAK1 interaction in pancreatic cancer cells.

Main Methods:

• Analysis of NUAK1 expression in pancreatic cancer tissues.
• Overexpression of miR-96 in MIA PaCa-2 pancreatic cancer cells.
• Bioinformatic prediction of miRNA target sites (miRanda, TargetScan, PicTar).
• Experimental validation of miR-96 targeting of NUAK1 3' UTR.
• Functional assays using modified NUAK1 cDNA lacking miR-96 binding sites.

Main Results:

• NUAK1 expression is significantly upregulated in pancreatic cancer and promotes proliferation, migration, and invasion of MIA PaCa-2 cells.
• Bioinformatic tools consistently predicted NUAK1 as a target of miR-96, binding to its 3' untranslated region (3' UTR).
• Experimental data confirmed that miR-96 directly suppresses NUAK1 expression by targeting its 3' UTR.
• Introduction of a NUAK1 variant lacking miR-96 binding sites abolished the inhibitory effects of miR-96 on cancer cell functions.

Conclusions:

• NUAK1 is an oncogene in pancreatic cancer, promoting tumor progression.
• miR-96 directly targets and downregulates NUAK1 expression in pancreatic cancer cells.
• The miR-96-mediated suppression of NUAK1 is a key mechanism underlying miR-96's tumor-suppressive functions in pancreatic cancer.